Rosenfeld Gabriel, Gabrielian Andrei, Hurt Darrell, Rosenthal Alex
Office of Cyber Infrastructure and Computational Biology, National Institutes of Allergy and Infectious Diseases, 5601 Fishers Lane, Rockville, MD 20852, USA.
Eur J Radiol Open. 2023 Sep 27;11:100518. doi: 10.1016/j.ejro.2023.100518. eCollection 2023 Dec.
This study compares performance of Timika Score to standardized, detailed radiologist observations of Chest X rays (CXR) for predicting early infectiousness and subsequent treatment outcome in drug sensitive (DS) or multi-drug resistant (MDR) tuberculosis cases. It seeks improvement in prediction of these clinical events through these additional observations.
This is a retrospective study analyzing cases from the NIH/NIAID supported TB Portals database, a large, trans-national, multi-site cohort of primarily drug-resistant tuberculosis patients. We analyzed patient records with sputum microscopy readings, radiologist annotated CXR, and treatment outcome including a matching step on important covariates of age, gender, HIV status, case definition, Body Mass Index (BMI), smoking, drug use, and Timika Score across resistance type for comparison.
2142 patients with tuberculosis infection (374 with poor outcome and 1768 with good treatment outcome) were retrospectively reviewed. Bayesian ANOVA demonstrates radiologist observations did not show greater predictive ability for baseline infectiousness (0.77 and 0.74 probability in DS and MDR respectively); however, the observations provided superior prediction of treatment outcome (0.84 and 0.63 probability in DS and MDR respectively). Estimated lung abnormal area and cavity were identified as important predictors underlying the Timika Score's performance.
Timika Score simplifies the usage of baseline CXR for prediction of early infectiousness of the case and shows comparable performance to using detailed, standardized radiologist observations. The score's utility diminishes for treatment outcome prediction and is exceeded by the usage of the detailed observations although prediction performance on treatment outcome decreases especially in MDR TB cases.
本研究比较了蒂米卡评分与放射科医生对胸部X光(CXR)进行标准化、详细观察的结果,以预测药物敏感(DS)或耐多药(MDR)结核病病例的早期传染性和后续治疗结果。本研究旨在通过这些额外的观察来改进对这些临床事件的预测。
这是一项回顾性研究,分析了来自美国国立卫生研究院/美国国立过敏与传染病研究所支持的结核病门户数据库的病例,该数据库是一个大型的、跨国的、多地点的队列,主要是耐药结核病患者。我们分析了患者记录,包括痰涂片显微镜检查结果、放射科医生标注的CXR以及治疗结果,包括对年龄、性别、HIV状态、病例定义、体重指数(BMI)、吸烟、药物使用和不同耐药类型的蒂米卡评分等重要协变量进行匹配步骤,以进行比较。
对2142例结核感染患者(374例预后不良,1768例治疗效果良好)进行了回顾性分析。贝叶斯方差分析表明,放射科医生的观察结果对基线传染性的预测能力并不更强(DS和MDR中分别为0.77和0.74的概率);然而,这些观察结果对治疗结果的预测更好(DS和MDR中分别为0.84和0.63的概率)。估计的肺部异常面积和空洞被确定为蒂米卡评分表现的重要预测因素。
蒂米卡评分简化了使用基线CXR预测病例早期传染性的过程,并且与使用详细的、标准化的放射科医生观察结果表现相当。该评分在治疗结果预测方面的效用降低,尽管在耐多药结核病病例中治疗结果的预测性能尤其下降,但详细观察结果的使用在预测治疗结果方面更具优势。